Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739692 | 0.87 | CYP3A4 (0.59) | CYP3A4TRPA1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL11278919 | 0.84 | CYP3A4 (0.56) | CYP3A4TRPA1LMNAALDH1A1TDP1 | |
| SCHEMBL5653049 | 0.83 | CYP3A4 (0.54) | CYP3A4TRPA1LMNAALDH1A1TDP1 | |
| SCHEMBL2658282 | 0.81 | PTGS2 (0.40) | CYP3A4TRPA1PTGS2 | |
| SCHEMBL13556579 | 0.80 | CYP3A4 (0.51) | CYP3A4TRPA1LMNAALDH1A1TDP1 | |
| SCHEMBL27903840 | 0.79 | PTGS2 (0.40) | LMNAALDH1A1PTGS2SMN1; SMN2TDP1 | |
| SCHEMBL13104445 | 0.79 | IDH1 (0.50) | CYP3A4TRPA1PTGS2 | |
| SCHEMBL1190278 | 0.77 | LMNA (0.44) | CYP3A4TRPA1LMNAALDH1A1PTGS2 | |
| SCHEMBL30163034 | 0.76 | CA12 (0.53) | CYP3A4TRPA1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL10869858 | 0.75 | CYP3A4 (0.68) | CYP3A4TRPA1LMNAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885LMNA 3643/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885LMNA 3643/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885LMNA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.